ECCO 2023 POSTER

Patient-derived organoids as an epithelial model for preclinical IBD research and drug development

Patient-derived organoids (PDO) have emerged as a promising tool for drug development in inflammatory bowel diseases (IBD). These 3D in vitro models, derived from patient tissue, accurately mimic the cellular and molecular complexity of the intestine. Unlike traditional models like Caco cells, PDOs fully replicate the physiology of the intestinal barrier as they maintain patient-specific genetic and epigenetic features, cell-to-cell interactions, and organ-level architecture. 

Download our poster to learn about: 

• Our established IBD biobank which consists of key epithelial cell lineages involved in IBD pathophysiology 
• Our unique PDO intestinal monolayer platform for testing barrier integrity 
• Our available data comparing the performance of our PDO intestinal monolayer to the current standard of care (SoC)